

Arrowhead Pharmaceuticals, Inc. Investor Relations Department 225 South Lake Avenue Suite 1050 Pasadena, CA 91101 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: ARWR	
Last Trade:	3.95
Trade Time:	1:03 PM ET Oct 17, 2017
Change:	0.06 🕈 (+1.542%)
Day Range	3.79 - 4.05
52-Week Range	1.20 - 6.86
Volume	404,441

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAibased therapeutics leverage this natural pathway of gene silencing.

... (more)

Stock Performance



Press Releases [View all]

Oct 10, 2017

Arrowhead Pharmaceuticals to Present
Preclinical Data on ARO-AAT at The Liver
Meeting®

Oct 3, 2017

Arrowhead to Present at Chardan Gene
Therapy Conference

Sep 27, 2017

Arrowhead Data Reveal Important
Considerations for Future Hepatitis B
Treatment

Sep 14, 2017

<u>Arrowhead Hosts Investor & Analyst R&D</u>
<u>Day to Introduce TRiM™ Platform and Lead</u>
RNAi-based Drug Candidates

Sep 11, 2017

Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference

Upcoming Events [View all]

Oct 20–24, 2017
Preclinical Data on ARO-AAT

Financials [View all]

Third Quarter Financial Results

Dec 14, 2016

Annual Report (10-K)

Feb 1, 2017

Proxy Statement (DEF 14A)

Aug 3, 2017

Quarterly Report (10-Q)

May 3, 2017

Quarterly Report (10-Q)

Feb 6, 2017

Quarterly Report (10-Q)